GHK-Cu vs BPC-157
Research Comparison

Research Overview

GHK-Cu and BPC-157 are compared because the catalog carries each one alone and both together in two blends. The GHK-Cu research peptide is the copper(II) complex of Gly-His-Lys, a tripeptide isolated from human plasma (Pickart et al., 1980). The BPC-157 research peptide is a synthetic 15-residue partial sequence of a protein isolated from human gastric juice (Chang et al., 2011).

Beyond the shared vial, their literatures ask different questions: copper delivery, fibroblast matrix synthesis and gene-expression screens for GHK-Cu; nitric oxide (NO), gastric and tendon models in rats, mostly from one group, for BPC-157. Nearly all of it is cell or animal work, and a PubMed search on 9 October 2026 found no study that tested the two together.

Structure and Class

GHK-Cu is glycyl-L-histidyl-L-lysine holding one copper(II) ion, which makes up about 16 percent of its mass. Its product page lists C14H22CuN6O4, 401.91 g/mol; the free GHK peptide is C14H24N6O4, about 340.38 g/mol (PubChem CID 73587). In solution the copper is held by the N-terminal amine, a backbone amide nitrogen and the histidine imidazole (Hureau et al., 2011).

BPC-157 is a linear pentadecapeptide, GEPPPGKPADDAGLV, with no metal. Its product page lists C62H98N16O22, 1419.55 g/mol; PubChem CID 9941957 gives 1419.5 g/mol. BPC stands for body protection compound, the name given to the parent gastric protein.

The mass gap matters in any side-by-side design: one milligram holds about 2.5 µmol of GHK-Cu but only 0.70 µmol of BPC-157. The GLOW peptide blend holds 50MG GHK-Cu, 10MG BPC-157 and 10MG TB-500 as lyophilized powder, and the KLOW peptide blend adds 10MG KPV, as listed on the two product pages. From the label masses, either vial holds roughly 124 µmol GHK-Cu and 7 µmol BPC-157, about 18 to 1.

Side by Side

Research Context: GHK-Cu

During isolation from plasma, GHK co-purified with roughly equimolar copper. The tripeptide readily formed copper(II) complexes and increased copper uptake into cultured hepatoma cells; the authors likened its histidyl-lysyl arrangement to the copper transport site of albumin (Pickart et al., 1980).

In fibroblast cultures, GHK-Cu stimulated collagen synthesis starting between 10⁻¹² and 10⁻¹¹ M and peaking near 10⁻⁹ M, independent of any change in cell number (Maquart et al., 1988).

Profiling lung tissue from smokers with COPD, one gene-expression study linked 127 genes to regional emphysema severity and used the Connectivity Map to identify GHK as a compound that can reverse that signature. In cultured human lung fibroblasts, free GHK (the study did not test the copper complex) reproduced TGF-beta-induced expression patterns and organized the actin cytoskeleton (Campbell et al., 2012).

In lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages and in mice with LPS-induced acute lung injury, GHK-Cu lowered reactive oxygen species, TNF-alpha and IL-6 and suppressed NF-kappaB p65 and p38 MAPK signaling (Park et al., 2016).

No single group dominates. In a PubMed search on 9 October 2026 for GHK-Cu and its chemical names, the most frequent author on about 280 records, L. Pickart, appears on 17. A 2026 evidence-mapping review cautions that much of the literature handles GHK-Cu as one defined substance even though coordination state and labile copper vary with formulation, and that clinical evidence remains sparse (Mateescu et al., 2026).

Research Context: BPC-157

Early work centers on the NO system. In rats with ethanol-induced gastric lesions, the NO synthesis inhibitor L-NAME abolished the effect of L-arginine but only weakened that of BPC-157. In rat gastric mucosa homogenates, BPC-157 at 100 µM generated NO at a level comparable to L-arginine, and L-NAME did not block it even at a tenfold higher concentration (Sikiric et al., 1997).

An independent group in Taiwan studied tendon cells. BPC-157 accelerated outgrowth from rat Achilles tendon explants, raised fibroblast survival under hydrogen peroxide stress without changing proliferation, and increased fibroblast migration, spreading and F-actin formation, with FAK and paxillin phosphorylation rising with concentration (Chang et al., 2011).

In a PubMed search on 9 October 2026 for BPC-157 or its code PL 14736, about three in four of roughly 230 records list P. Sikiric, of the Zagreb group that described the peptide, as an author. An outside review noted that most studies used small rodent models and that only a handful of groups had studied the peptide in depth (Gwyer et al., 2019). Human data are thin: a 2025 review counted three small pilot studies and found rigorous, large-scale trials lacking (McGuire et al., 2025).

Choosing Between Them for a Research Question

Pick by question first. Copper coordination, copper uptake into cells, collagen synthesis in fibroblast culture and expression-signature screens have direct precedent with GHK-Cu or free GHK. The NO system, rat gastric lesion models and tendon fibroblast migration with FAK-paxillin signaling have direct precedent with BPC-157.

The cited studies overlap on one readout, in different models: actin cytoskeleton organization with free GHK in human lung fibroblasts (Campbell et al., 2012) and F-actin formation with BPC-157 in rat tendon fibroblasts (Chang et al., 2011). A direct comparison needs one cell source, matched molar concentrations and the endpoints of both.

GHK-Cu also brings a variable that BPC-157 does not: copper. The tripeptide increased copper uptake into cultured cells (Pickart et al., 1980), and the 2026 review argues for separating free GHK, the intact complex and free copper before an effect is attributed (Mateescu et al., 2026). In practice that means a free-GHK arm and a copper-salt arm beside the complex.

Blends need the same care. In GLOW and KLOW, GHK-Cu outnumbers BPC-157 about 18 to 1 by moles and shares the vial with TB-500, and with KPV in KLOW, so an effect seen with a blend cannot be assigned to either peptide without single-component arms. The GLOW vs KLOW comparison covers both blends.

Handling and Storage

Both product pages list -20°C for the lyophilized powder as shipped and 2 to 8°C after reconstitution, protected from light, with freeze/thaw cycles avoided. Let the sealed vial reach room temperature before opening so moisture does not condense on the cake, add diluent slowly down the vial wall, and swirl rather than shake.

GHK-Cu stayed stable in water and in pH 4.5 to 7.4 buffers for at least two weeks at 60°C, but basic and oxidative stress drove hydrolytic cleavage, with histidine among the degradation products (Badenhorst et al., 2016). It also exchanges copper quickly and forms ternary complexes with glycine or histidine (Hureau et al., 2011), so chelators and amino-acid buffers can change what is in solution.

BPC-157 contains no cysteine or methionine, so there is no disulfide to protect and no thioether to oxidize. Anti-doping work found it in confiscated vials and showed a stable metabolite forming in plasma (Cox et al., 2017), so prepare biological-matrix samples fresh and keep them cold. For both, split stock into single-use aliquots, record the lot number, and base molar calculations on the measured content in the lot certificate from the COA portal.

Questions Researchers Ask

GHK-Cu vs BPC-157: what is the difference?

Structure, origin and research line. GHK-Cu is a 401.91 g/mol copper complex of a plasma tripeptide, studied in copper-uptake, fibroblast and gene-expression work. BPC-157 is a 1419.55 g/mol gastric protein fragment with no metal, studied mostly in rat tissue models. The GHK-Cu research guide and the BPC-157 research guide cover each in depth.

GHK-Cu or BPC-157: which has more independent research?

GHK-Cu. Its PubMed records spread across many groups, while about three in four BPC-157 records list one Zagreb investigator, and an outside review found that only a handful of groups had studied BPC-157 in depth (Gwyer et al., 2019).

BPC-157 vs GHK-Cu: has anyone studied them together?

Not in a published study. A PubMed search on 9 October 2026 found no experiment combining the two and no study of the GLOW or KLOW blends; the records that name both are reviews.

Are GHK-Cu and BPC-157 restricted?

The WADA Prohibited List for 2026 names BPC-157 in class S0, non-approved substances, prohibited at all times. GHK-Cu is not named, though WADA notes the S0 class is not limited to the substances it names. An FDA page on bulk drug substances that may present significant safety risks lists both among former category 2 substances whose nominations the nominators withdrew, GHK-Cu for injectable routes only.